Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Combination therapies in prostate cancer: proceed with caution.

Spratt DE.

Lancet Oncol. 2019 Mar;20(3):321-323. doi: 10.1016/S1470-2045(18)30929-X. Epub 2019 Feb 6. No abstract available.

PMID:
30738781
2.

Prostate cancer: HIFU as primary treatment for prostate cancer: proceed with caution.

Ray K.

Nat Rev Urol. 2011 May;8(5):234. doi: 10.1038/nrurol.2011.58. No abstract available.

PMID:
21562477
3.

Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution?

Abern MR, Freedland SJ.

Eur Urol. 2013 Feb;63(2):210-1; discussion 212-3. doi: 10.1016/j.eururo.2012.09.002. Epub 2012 Sep 10. No abstract available.

PMID:
23018162
4.

Active surveillance for African-American men with prostate cancer: proceed with caution. Con.

Sundi D, Schaeffer EM.

Oncology (Williston Park). 2014 Jan;28(1):83, 85. No abstract available.

5.

Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate.

Collins MM, Barry MJ.

JAMA. 1996 Dec 25;276(24):1976-9. Review.

PMID:
8971068
6.

Complementary and alternative therapies in prostate cancer.

Oh WK, Small EJ.

Semin Oncol. 2002 Dec;29(6):575-84. Review.

PMID:
12516040
7.

Combination of inhaled corticosteroid and a long-acting β-agonist: Proceed with caution.

Weinberger M.

Ann Allergy Asthma Immunol. 2019 Mar;122(3):350. doi: 10.1016/j.anai.2018.11.019. No abstract available.

PMID:
30798852
8.

Proceed with caution.

Rankin-Box D.

Nurs Times. 1991 Nov 6-12;87(45):34-6. No abstract available.

PMID:
1956832
9.

Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?

Labuzek K, Kozłowski M, Szkudłapski D, Sikorska P, Kozłowska M, Okopień B.

Eur J Intern Med. 2013 Apr;24(3):207-12. doi: 10.1016/j.ejim.2013.01.009. Epub 2013 Jan 31. Review.

PMID:
23375875
10.
11.

Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.

Lou DY, Fong L.

Urol Oncol. 2016 Apr;34(4):182-92. doi: 10.1016/j.urolonc.2013.12.001. Epub 2014 Feb 2. Review.

12.

Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.

Cirak Y, Varol U, Atmaca H, Kisim A, Sezgin C, Karabulut B, Uzunoglu S, Uslu R, Karaca B.

BJU Int. 2012 Dec;110(11 Pt C):E1147-54. doi: 10.1111/j.1464-410X.2012.11392.x. Epub 2012 Aug 9.

13.

Complementary and alternative therapies.

Cassileth BR, Vickers AJ.

Urol Clin North Am. 2003 May;30(2):369-76. Review.

PMID:
12735512
14.

Attitudes and use of alternative therapies in UK prostate cancer patients-isn't it time we were in the know?

Cheetham PJ, Le Monnier KJ, Brewster SF.

Prostate Cancer Prostatic Dis. 2001;4(4):235-241.

15.

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.

Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.

Clin Cancer Res. 2004 Jul 1;10(13):4398-405.

16.

Changing face of metastatic prostate cancer: the law of diminishing returns holds true.

Vaishampayan UN.

Curr Opin Oncol. 2017 Mar 18. doi: 10.1097/CCO.0000000000000370. [Epub ahead of print]

PMID:
28323658
17.

Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer.

Clarke DM, Baust JM, Van Buskirk RG, Baust JG.

Cryobiology. 2001 Jun;42(4):274-85.

PMID:
11748936
18.

Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.

Ramsay CR, Adewuyi TE, Gray J, Hislop J, Shirley MD, Jayakody S, MacLennan G, Fraser C, MacLennan S, Brazzelli M, N'Dow J, Pickard R, Robertson C, Rothnie K, Rushton SP, Vale L, Lam TB.

Health Technol Assess. 2015 Jul;19(49):1-490. doi: 10.3310/hta19490. Review.

19.

Changing patterns of CAM use among prostate cancer patients two years after diagnosis: reasons for maintenance or discontinuation.

Porter M, Kolva E, Ahl R, Diefenbach MA.

Complement Ther Med. 2008 Dec;16(6):318-24. doi: 10.1016/j.ctim.2008.04.001. Epub 2008 Jun 9.

PMID:
19028331
20.

Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy.

Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P.

BJU Int. 2009 Aug;104(4):490-7. doi: 10.1111/j.1464-410X.2009.08359.x. Epub 2009 Feb 10.

Supplemental Content

Support Center